Cargando…
Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864431/ https://www.ncbi.nlm.nih.gov/pubmed/33476333 http://dx.doi.org/10.1371/journal.pgen.1009113 |
_version_ | 1783647661761495040 |
---|---|
author | Sakimura, Shotaro Nagayama, Satoshi Fukunaga, Mitsuko Hu, Qingjiang Kitagawa, Akihiro Kobayashi, Yuta Hasegawa, Takanori Noda, Miwa Kouyama, Yuta Shimizu, Dai Saito, Tomoko Niida, Atsushi Tsuruda, Yusuke Otsu, Hajime Matsumoto, Yoshihiro Uchida, Hiroki Masuda, Takaaki Sugimachi, Keishi Sasaki, Shin Yamada, Kazutaka Takahashi, Kazuki Innan, Hideki Suzuki, Yutaka Nakamura, Hiromi Totoki, Yasushi Mizuno, Shinichi Ohshima, Masanobu Shibata, Tatsuhiro Mimori, Koshi |
author_facet | Sakimura, Shotaro Nagayama, Satoshi Fukunaga, Mitsuko Hu, Qingjiang Kitagawa, Akihiro Kobayashi, Yuta Hasegawa, Takanori Noda, Miwa Kouyama, Yuta Shimizu, Dai Saito, Tomoko Niida, Atsushi Tsuruda, Yusuke Otsu, Hajime Matsumoto, Yoshihiro Uchida, Hiroki Masuda, Takaaki Sugimachi, Keishi Sasaki, Shin Yamada, Kazutaka Takahashi, Kazuki Innan, Hideki Suzuki, Yutaka Nakamura, Hiromi Totoki, Yasushi Mizuno, Shinichi Ohshima, Masanobu Shibata, Tatsuhiro Mimori, Koshi |
author_sort | Sakimura, Shotaro |
collection | PubMed |
description | A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC. |
format | Online Article Text |
id | pubmed-7864431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78644312021-02-12 Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases Sakimura, Shotaro Nagayama, Satoshi Fukunaga, Mitsuko Hu, Qingjiang Kitagawa, Akihiro Kobayashi, Yuta Hasegawa, Takanori Noda, Miwa Kouyama, Yuta Shimizu, Dai Saito, Tomoko Niida, Atsushi Tsuruda, Yusuke Otsu, Hajime Matsumoto, Yoshihiro Uchida, Hiroki Masuda, Takaaki Sugimachi, Keishi Sasaki, Shin Yamada, Kazutaka Takahashi, Kazuki Innan, Hideki Suzuki, Yutaka Nakamura, Hiromi Totoki, Yasushi Mizuno, Shinichi Ohshima, Masanobu Shibata, Tatsuhiro Mimori, Koshi PLoS Genet Research Article A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC. Public Library of Science 2021-01-21 /pmc/articles/PMC7864431/ /pubmed/33476333 http://dx.doi.org/10.1371/journal.pgen.1009113 Text en © 2021 Sakimura et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sakimura, Shotaro Nagayama, Satoshi Fukunaga, Mitsuko Hu, Qingjiang Kitagawa, Akihiro Kobayashi, Yuta Hasegawa, Takanori Noda, Miwa Kouyama, Yuta Shimizu, Dai Saito, Tomoko Niida, Atsushi Tsuruda, Yusuke Otsu, Hajime Matsumoto, Yoshihiro Uchida, Hiroki Masuda, Takaaki Sugimachi, Keishi Sasaki, Shin Yamada, Kazutaka Takahashi, Kazuki Innan, Hideki Suzuki, Yutaka Nakamura, Hiromi Totoki, Yasushi Mizuno, Shinichi Ohshima, Masanobu Shibata, Tatsuhiro Mimori, Koshi Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title | Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title_full | Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title_fullStr | Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title_full_unstemmed | Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title_short | Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases |
title_sort | impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in crc cases |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864431/ https://www.ncbi.nlm.nih.gov/pubmed/33476333 http://dx.doi.org/10.1371/journal.pgen.1009113 |
work_keys_str_mv | AT sakimurashotaro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT nagayamasatoshi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT fukunagamitsuko impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT huqingjiang impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT kitagawaakihiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT kobayashiyuta impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT hasegawatakanori impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT nodamiwa impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT kouyamayuta impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT shimizudai impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT saitotomoko impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT niidaatsushi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT tsurudayusuke impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT otsuhajime impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT matsumotoyoshihiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT uchidahiroki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT masudatakaaki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT sugimachikeishi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT sasakishin impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT yamadakazutaka impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT takahashikazuki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT innanhideki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT suzukiyutaka impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT nakamurahiromi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT totokiyasushi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT mizunoshinichi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT ohshimamasanobu impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT shibatatatsuhiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases AT mimorikoshi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases |